

STATUS OF THE CLAIMS

- 1.-16. Cancelled.
17. (Currently Amended) A method of treating ~~tumor~~, viral or bacterial infections, ~~or~~ inflammatory diseases, or a tumor, ~~wherein said tumor cells or cells affected by said infection or inflammation bear Hsp70 on their surface~~, said method comprising:
 - (a) administering a pharmaceutical composition comprising a pharmaceutically effective amount of isolated granzyme B as the only pharmaceutically active component to a human in need thereof cells affected by said infection or inflammatory diseases or tumor cells, said cells bearing Hsp70 on their surface;
 - (b) allowing granzyme B to enter said cells via ion channels formed by said Hsp70 on the ~~ee~~ll surface of said cells; and
 - (c) allowing said cells to undergo apoptosis as a result of the enzymatic activity of granzyme B.
- 18-24. (Cancelled).
25. (Currently Amended) The method of claim 17, wherein granzyme B is ~~administered~~ present in the pharmaceutical composition in a final concentration of 1 μ g/ml to 500 μ g/ml.
26. (Currently Amended) The method of claim 17, wherein granzyme B is ~~administered~~ present in the pharmaceutical composition in a final concentration of 1ng/ml to 10 ng/ml.
27. (Currently Amended) The method of claim 26 wherein granzyme B is ~~administered~~ present in the pharmaceutical composition in a final concentration of about 6 ng/ml.
28. (Previously Presented) The method of claim 17, wherein the viral infection is an infection by HIV or Hepatitis virus.
29. (New) A method of treating viral or bacterial infections, inflammatory diseases or a tumor, said method comprising:
 - a) administering a pharmaceutical composition comprising a pharmaceutically effective amount of isolated granzyme B as the only pharmaceutically active component to cells

affected by said infection or inflammation or tumor cells, said cells bearing Hsp70 on their surface;

b) allowing granzyme B to enter said cells via ion channels formed by Hsp70 on the cell surface; and

c) allowing said cells to undergo apoptosis as a result of the enzymatic activity of granzyme B, wherein said cells affected by said infection or inflammation or tumor cells are analyzed for surface expression of Hsp70.

30. (New) The method of claim 29, wherein granzyme B is present in the pharmaceutical composition in a final concentration of 1 μ g/ml to 500 μ g/ml.

31. (New) The method of claim 29, wherein granzyme B is present in the pharmaceutical composition in a final concentration of 1ng/ml to 10 ng/ml.

32. (New) The method of claim 31 wherein granzyme B is present in the pharmaceutical composition in a final concentration of about 6 ng/ml.

33. (New) The method of claim 29, wherein the viral infection is an infection by HIV or Hepatitis virus.